ReGen Therapeutics has modest but growing revenues from its nutraceutical Colostrinin and, through funding facilities in place, can finance its planned R&D activities this year. These comprise further work on its novel formulation of zolpidem for neurological dormancy and some early-stage research into peptides for Alzheimer’s and other conditions. Confirmation of a US mass market partner for Colostrinin and launches of the product elsewhere could provide significant upside.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here